MedTrace Logo

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

NCT02272738 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-11-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical safety and efficacy of Gemcitabine plus nab-Paclitaxel chemoradiotherapy and to determine the Maximal Tolerated Dose (MTD) for unresectable locally advanced pancreatic adenocarcinoma.

Conditions

Interventions

DRUG

Gemcitabine

Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.

DRUG

Nab-Paclitaxel

Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.

Sponsors & Collaborators

  • Osaka Medical Center for Cancer and Cardiovascular Diseases

    lead OTHER

Principal Investigators

  • Tatsuya Ioka, MD · Osaka Medical Center for Cancer and Cardiovascular Diseases

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-11-30
Completion
2016-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02272738 on ClinicalTrials.gov